Cyclosporine for Behçet's uveitis: Is it associated with an increased risk of neurological involvement?

Clinical and Experimental Rheumatology

Volumn 26, Issue 4 SUPPL. 50, 2008, Pages

  Akmar Demir, Gulsen ^a   Ayranci, Ozen ^a   Kurtuncu, Murat ^a   Vanli, Ebru N ^a   Mutlu, Melike ^a   Tugal Tutkun, Ilknur ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Beh et's disease; Cyclosporine; Neurological involvement

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; BEHCET DISEASE; BRAIN STEM; CEREBRAL SINUS THROMBOSIS; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG SUBSTITUTION; EPILEPSY; FEMALE; HEADACHE; HOSPITAL DEPARTMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; PATIENT SELECTION; PLEOCYTOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEIZURE; UVEITIS;

ADULT; BEHCET SYNDROME; BRAIN DISEASES; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; PROSPECTIVE STUDIES; UVEITIS; YOUNG ADULT;

EID: 55049093947     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. BEHÇET H: Uber die rezidivierende aphlose durch ein virus verursachte geschwüre am mund, am Auge und an den Genitalien. Derm Wochenschr 1937: 105: 1152-7.
2. SHIMIZU T, EHLICH G, INABA G, HAYASHI K: Behçet's disease (Behçet's syndrome). Semin Arthritis Rheum 1979: 8: 223-60.
3. MAMO FG: The rate of visual loss in Behçet's disease. Arch Ophthalmol 1970; 451-2.
4. TUGAL-TUTKUN I, ONAL S, ALTAN-YAYCIOGLU R, ALTUNBAS, H, URGANCIOGLU M: Uveitis in Behçet's disease: An analysis of 880 patients. Am J Ophthalmol 2004; 138; 373-80.
5. NUSSENBLATT RB, PALESTINE AG, ROOK AH, SCHER I, WACKER WB, GERY T: Treatment of intra-ocular inflammatory disease with cyclosporin A. Lancet 1983; ii: 235-8.
6. MASUDA K, URAYAMA A, KOGURE M, NAKAJIMA A, NAKAE K, INABA G: Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989; i: 1093-6.
7. ÖZYAZGAN Y, YURDAKUL S, YAZICI H et al.: Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: A single masked trial. Br J Ophthalmol 1992; 76: 241-3.
8. KATO Y, NUMAGA J, KATO S, KABURAKI T, KAWASHIMA H, FUJINO Y: Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A. Clin Exp Ophthalmol 2001; 29: 335-6.
9. KOTAKE S, HIGASHI K, YOSHIKAWA K, SASAMOTO Y, OKAMATO T, MATSUDA H: Central nervous system symptoms in patients with Behçet's disease receiving cyclosporine therapy. Ophthalmology 1999; 106: 586-9.
10. KÖTTER I, GUNAYDIN I, BATRA M et al.: CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporine A (CSA) than under other medications - results of a retrospective analysis of 117 cases. Clin Rheumatol 2006; 25: 482-6.
11. MITSUI Y, MITSUI M, URAKAMI R, KIHARA M, TAKAHASHI M, KUSUNOKI S: Behçet's disease presenting with neurological complications immediately after conversion from conventional cyclosporin A to a microemulsion formulation. Intern Med 2005; 44: 149-52.
12. INTERNATIONAL STUDY GROUP FOR BEHÇET'S DISEASE: Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
13. SERDAROGLU P, YAZICI H, OZDEMIR C, YURDAKUL S, BAHAR S, AKTIN E: Neurological involvement in Behçet's syndrome. A prospective study. Arch Neurol 1989; 46: 265-9.
14. SIVA A, KANTARCI OH, SAIP S et al.: Behçet's disease: Diagnostic and prognostic aspects of neurologic involvement. J Neurol 248: 95-103.
15. AKMAN DEMIR G, SERDAROGLU P, TASCI B and the NEURO-BEHÇET STUDY GROUP: Clinical patterns of neurologic involvement in Behçet's disease: Evaluation of 200 patients. Brain 1999; 122: 2171-81.
16. SAYLAN T, SALTIK I: Thalidomide in the treatment of Behyet's syndrome. Arch Dermatol 1982; 118: 536.
17. HAMURYUDAN V, MAT C, SAIP S et al.: Thalidomide in the treatment of the mucocutaneous lesions of Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443-50.
18. CHANG SH, LIM CH, LOW TS, CHONG HT, TAN SY: Cyclosporine-associated encephalopathy: A case report and literature review. Transpl Proc 2001; 33: 3700-1.
19. GIJTENBEEK JMM, VAN DEA BENT MJ, VECHT CJ: Cyclosporine neurotoxicity: a review. J Neurol 1999: 246: 339-46.
20. SERKOVA NJ, CHRISTIANS U, BENET LZ: Cyclosporine neurotoxicity. Mol Intervent 2004; 4: 97-107.
21. OZKAYA O, KALMAN S, BAKKALOGLU S, BUYAN N, SOYLEMEZOGLU O: Cyclo-sporine-associated facial paralysis in a child with renal transplant. Pediatr Nephrol 2002; 17: 544-6.
22. PORGES Y, BLUMEN S, FIREMAN Z, STERNBERG A, ZAMIR D: Cyclosporine-induced optic neuropathy, ophthalmoplegia and nystagmus in a patient with Crohn disease. Am J Ophthalmol 1998: 126: 607-9.
23. WIJDICKS EF, WIESNER RH, KROM RA: Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995; 45: 1962-4.
24. AYKUTLU E, BAYKAN B, SERDAROGLU P, GÖKYIGIT A, AKMAN-DEMIR G: Epileptic seizures in Behçet's disease. Epilepsia 2002; 43: 832-5.
25. AKMAN-DEMIR G, BAHAR S, COBAN O, TASCI B, SERDAROGLU P: Cranial MRI in Behçet's disease: 134 examinations of 98 patients. Neuroradiology 2003; 45: 851-9.
26. IGARASHI T, ISHIGATSUB0 Y, OHNO S et al.: CNS toxicity related to FK506 in patients with Behçet's disease. Ann Rheum Dis 1994; 53: 350-1